LATEST
  • image
    Review| Open Access

    Sphingolipid metabolism and drug resistance in ovarian cancer

    Kelly M. Kreitzburg, Robert C. A. M. van Waardenburg, Karina J. Yoon

    Despite progress in understanding molecular aberrations that contribute to the development and progression of ovarian cancer, virtually all patients succumb to drug resistant disease at relapse. Emerging data implicate bioactive sphingolipids and regulation of sphingolipid metabolism as... Read more

    Cancer Drug Resist 2018;1:181-97. | doi:10.20517/cdr.2018.06
    Published on: 19 Sep 2018  | Viewed:1181  | Downloaded:89
    +HTML| PDF
  • image
    Review| Open Access

    Molecular bases of Sorcin-dependent resistance to chemotherapeutic agents

    Ilaria Genovese, Andrea Ilari, Theo Battista, Valerio Chiarini, Francesco Fazi, Annarita Fiorillo, Gianni Colotti

    Soluble resistance-related calcium binding protein (Sorcin) is a protein initially labelled “resistance-related”, since it is co-amplified with ABCB1 in multidrug (MD)-resistant cells. While for years Sorcin overproduction was believed to be a by-product of the co-amplification of its gene with... Read more

    This article belongs to the Special Issue Targeted cancer therapy Cancer Drug Resist 2018;1:164-80. | doi:10.20517/cdr.2018.10
    Published on: 19 Sep 2018  | Viewed:540  | Downloaded:47
    +HTML| PDF
  • image
    Review| Open Access

    Glutamine metabolism in cancer therapy

    Tra-Ly Nguyen, Raúl V. Durán

    The amino acid glutamine plays a key role in the metabolism of highly proliferating cells. During malignant transformation, cancer cells modify the consumption and processing of glutamine to sustain cell growth and proliferation. In some cases, these cancer cells become addicted to glutamine.... Read more

    This article belongs to the Special Issue Targeted cancer therapy Cancer Drug Resist 2018;1:126-38. | doi:10.20517/cdr.2018.08
    Published on: 19 Sep 2018  | Viewed:122  | Downloaded:23
    +HTML| PDF
  • image
    Opinion| Open Access

    Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses

    Natalia J Gurule, Lynn E. Heasley

    Receptor tyrosine kinases (RTKs) bearing oncogenic mutations in EGFR, ALK and ROS1 occur in a significant subset of lung adenocarcinomas. Tyrosine kinase inhibitors (TKIs) targeting tumor cells dependent on these oncogenic RTKs yield tumor shrinkage, but also a variety of adverse events. Skin... Read more

    This article belongs to the Special Issue Targeted cancer therapy Cancer Drug Resist 2018;1:118-25. | doi:10.20517/cdr.2018.12
    Published on: 19 Sep 2018  | Viewed:778  | Downloaded:87
    +HTML| PDF
  • image
    Review| Open Access

    Hitting a moving target: inhibition of the nuclear export receptor XPO1/CRM1 as a therapeutic approach in cancer

    Maria Sendino, Miren Josu Omaetxebarria, Jose Antonio Rodríguez

    Cellular homeostasis crucially relies on the correct nucleocytoplasmic distribution of a vast number of proteins and RNA molecules, which are shuttled in and out of the nucleus by specialized transport receptors. The nuclear export receptor XPO1, also called CRM1, mediates the translocation of... Read more

    This article belongs to the Special Issue Targeted cancer therapy Cancer Drug Resist 2018;1:139-63. | doi:10.20517/cdr.2018.09
    Published on: 19 Sep 2018  | Viewed:174  | Downloaded:19
    +HTML| PDF
  • image
    Editorial| Open Access

    Targeted therapies in cancer: where are we going?

    Elisa Giovannetti, Jose A. Rodriguez This article belongs to the Special Issue Targeted cancer therapy Cancer Drug Resist 2018;1:82-6. | doi:10.20517/cdr.2018.05
    Published on: 19 Jun 2018  | Viewed:967  | Downloaded:68
    +HTML| PDF
  • image
    Review| Open Access

    Drug targets and resistance mechanisms in multiple myeloma

    Janine Nass, Thomas Efferth

    Multiple myeloma (MM), a malignancy of plasma cells, is the second most prevalent blood cancer (10%). A PubMed search has been conducted for English research papers and reviews published until January 2018. Numerous drugs are used in treatment of MM. These include the antineoplastic alkylating... Read more

    Cancer Drug Resist 2018;1:87-117. | doi:10.20517/cdr.2018.04
    Published on: 19 Jun 2018  | Viewed:1834  | Downloaded:115
    +HTML| PDF
  • image
    Original Article| Open Access

    Resistance mechanism to cisplatin in NCI-H460 non-small cell lung cancer cell line: investigating apoptosis, autophagy, and cytogenetic damage

    Érica Ballestreri, Daniel Simon, Ana Paula de Souza, Camila Schultz Grott, Débora Dreher Nabinger, Rafael Rodrigues Dihl, Ivana Grivicich

    Aim: To investigate the effects of cisplatin on the human non-small cell lung carcinoma (NCI-H460) cell line regarding cytotoxicity, genotoxicity, and expression of genes associated with apoptosis (BIRC5) and autophagy (BECN1). Methods: Cell cultures were treated with cisplatin concentrations... Read more

    Cancer Drug Resist 2018;1:72-81. | doi:10.20517/cdr.2017.02
    Published on: 19 Mar 2018  | Viewed:2040  | Downloaded:139
    +HTML| PDF
  • image
    Original Article| Open Access

    Reduction of mitomycin C resistance in human bladder cancer T24 cells by knocking-down ras oncogene

    Osama Sharaf Eldin, Abdel-Motaal Fouda, Amany R. Youssef, Peter Hamilton, Perry Maxwell, Kate E. Williamson

    Aim: Mitomycin C (MMC) is a commonly used as intravesical treatment for superficial bladder cancer. However, its role in combination with ras inhibition has not been investigated. The aim of this study was to explore the role of ras in MMC-induced apoptosis in T24 bladder cancer cells and to... Read more

    Cancer Drug Resist 2018;1:59-71. | doi:10.20517/cdr.2017.01
    Published on: 19 Mar 2018  | Viewed:2527  | Downloaded:85
    +HTML| PDF
  • image
    Original Article| Open Access

    Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations

    Anthony Dominijanni, William H. Gmeiner

    Aim: Resistance to fluoropyrimidine drugs (FPs) is a major cause of mortality in colorectal cancer (CRC). We assessed the potency advantage of the polymeric FP F10 relative to 5-fluorouracil (5-FU) in four human CRC cell lines that differ only in TP53 mutational status to determine how p53... Read more

    Cancer Drug Resist 2018;1:48-58. | doi:10.20517/cdr.2018.01
    Published on: 19 Mar 2018  | Viewed:2047  | Downloaded:91
    +HTML| PDF

Submit an article to CDR

CDR publishes pharmacological aspects of drug resistance and its reversal, including drug design, drug delivery, drug distribution and cellular drug resistance. Molecular mechanisms of drug resistance also cover the cellular pharmacology of drug resistance such as influx and efflux pumps (including the ABC pumps), receptors and their ligands, cellular signaling pathways, drug activation and degradation (including Phase I and II metabolism), drug sequestration, target modification and DNA repair. Drug classes to be covered include DNA targeted drugs and antihormones as well as antibodies and protein kinase inhibitors. Both clinical and experimental aspects of drug resistance in cancer are included.

Learn more about the journal and author instructions or get started with your submission.

SUBMIT YOUR PAPER

Subscribe

To receive email updates about the journal, please subscribe here.

Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.